Indivior Pharmaceuticals, Inc. (INDV) research

Indivior Pharmaceuticals, Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$35.91
As of

Indivior Pharmaceuticals, Inc. (INDV): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-17.

As of . Source: SEC EDGAR filings for INDV. Method and limitations.

SHARE THIS CARD

Share the INDV intelligence card

A branded snapshot of INDV: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion INDV intelligence card preview
Post to X
LIVE TERMINAL

See INDV live in the terminal

Track INDV's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live INDV terminal, free

Active signals for INDV

FREE, NO ACCOUNT

Every signal on INDV, as it fires

You are seeing 5 of 41 signals recorded on INDV since 2026-05-31.

The five above landed across 2 days. The other 36 were recorded on 4 other days. 30 of the 41 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in INDV (2026Q2)

Manager / securityMarket value% portfolioQoQ
CITADEL ADVISORS LLCCUSIP 45579U109 · 2026Q2$109.5M0.01%,
MILLENNIUM MANAGEMENT LLCCUSIP 45579U109 · 2026Q2$86.1M0.03%,
Point72 Asset Management, L.P.CUSIP 45579U109 · 2026Q2$51.3M0.06%,
TWO SIGMA INVESTMENTS, LPCUSIP 45579U109 · 2026Q2$12.8M0.01%,
D. E. Shaw & Co., Inc.CUSIP 45579U109 · 2026Q2$9.7M0.00%,
Bridgewater Associates, LPCUSIP 45579U109 · 2026Q2$2.8M0.01%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, INDV

INDV against its peers

INDV's operating margin of 21.1% ranks in the 87th percentile of 18 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-05-31.

MetricINDVPeer medianPercentilen
Revenue FY1.2B USD567M USD8218
Revenue YoYn/a-3.1%n/a6
Gross margin80.2%49.8%9715
Operating margin21.1%-0.7%8718
Net margin16.9%-5.8%8819
Return on equityn/a-7.5%n/a17
P / E21.9xn/an/a3

Peers (21): RGC, KNSA, CURLF, HCM, PBH, ALVO, PRGO, ETON, GTBIF, ELAN, HROW, CRON, TLRY, VREOF, AQST, EOLS, KMDA, TKNO, NIKA, VRNO, HLN. Left out: HYPMY (no annual filing), RDY (period gap), SGIOF (no annual filing), EVO (period gap). Fiscal periods ending between 2025-06-30 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (INDV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more INDV signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to INDVand get the insider, 13F, options, and confluence read in one view.

Open the live INDV terminal, free